Skip to content
Cancidas, Cancidas (previously caspofungin msd)(caspofungin)
Cancidas (caspofungin) is a small molecule pharmaceutical. Caspofungin was first approved as Cancidas on 2001-01-26. It is used to treat aspergillosis, candidemia, and mycoses in the USA. It has been approved in Europe to treat aspergillosis and candidiasis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Cancidas (generic drugs available since 2017-09-29)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Caspofungin acetate
Tradename
Company
Number
Date
Products
CASPOFUNGIN ACETATEFresenius KabiN-206110 RX2016-12-30
2 products
CANCIDASMerck KGaAN-021227 RX2001-01-26
2 products, RLD, RS
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
aspergillosisEFO_0007157D001228B44
candidemiaEFO_1001282D058387—
mycoses—D009181B35-B49
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Caspofungin Acetate, Caspofungin Acetate, Fresenius Kabi Usa
96364072032-12-21DP
ATC Codes
J: Antiinfectives for systemic use
— J02: Antimycotics for systemic use
— J02A: Antimycotics for systemic use
— J02AX: Other antimycotics for systemic use in atc
— J02AX04: Caspofungin
HCPCS
Code
Description
J0637
Injection, caspofungin acetate, 5 mg
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181B35-B49—7101220
Invasive candidiasisD058365EFO_1001283B37—441—9
CandidemiaD058387EFO_1001282—141—6
Invasive pulmonary aspergillosisD055744B44.013—216
Liver transplantationD016031EFO_0010682—111—3
Critical illnessD016638———123
Pneumocystis pneumoniaD011020EFO_0007448B59———112
Hematologic neoplasmsD019337———1—1
Invasive hydatidiform moleD002820D39.2———1—1
Liver diseasesD008107EFO_0001421K70-K77———1—1
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CandidiasisD002177B37—45—211
FungemiaD016469B49—22——4
NeutropeniaD009503D70—12—14
NeoplasmsD009369C80—21——3
Myeloid leukemia acuteD015470C92.0111——2
LeukemiaD007938C95——1—12
Oral candidiasisD002180EFO_0007406B37.0—11——2
Intraabdominal infectionsD059413——1——1
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0——1——1
Monocytic leukemia acuteD007948——1——1
Show 3 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—1——34
AspergillosisD001228EFO_0007157B44—3——14
Hiv infectionsD015658EFO_0000764B20—1——12
Hematopoietic stem cell transplantationD018380—1———1
FeverD005334HP_0001945R50.9—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Invasive fungal infectionsD000072742————33
Septic shockD012772A48.3————11
ShockD012769R57.1————11
FusariosisD060585EFO_1001795————11
SarcomaD012509————11
LymphomaD008223C85.9————11
NeuroblastomaD009447EFO_0000621————11
Kidney neoplasmsD007680EFO_0003865C64————11
Hot flashesD019584————11
PharmacokineticsD010599————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCASPOFUNGIN
INNcaspofungin
Description
Caspofungin (INN; brand name Cancidas) is a lipopeptide antifungal drug from Merck & Co., Inc. discovered by James Balkovec, Regina Black and Frances A. Bouffard. It is a member of a new class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin was the first inhibitor of fungal (1→3)-β-D-glucan synthesis to be approved by the United States Food and Drug Administration. Caspofungin is administered intravenously.
Classification
Small molecule
Drug classantifungal antibiotics (undefined group)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O
Identifiers
PDB—
CAS-ID162808-62-0
RxCUI—
ChEMBL IDCHEMBL499808
ChEBI ID474180
PubChem CID468682
DrugBankDB00520
UNII IDF0XDI6ZL63 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Cancidas - Merck Sharp & Dohme
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 10,228 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
17 adverse events reported
View more details